StockData
Medline Inc. logo

Medline Inc. (MDLN) KPIs and segments

MDLNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 2/3060% above fair value
$39.16+1.48 (+3.93%)

Close on Nov 18, 2026Market cap $51.48BP/E –Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Medline · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Medline: 38 chỉ số vận hành, trong đó có Prime Vendor Net Sales, Total New Customer Signings và Organic Net Sales Growth, lấy từ 27 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Supply Chain Solutions($M)
4,1453,8873,5643,380
Medline Brand($M)
3,5403,4653,3223,264
Acute care($M)
5,4075,1254,7164,572
Non-Acute care($M)
1,7451,7321,6831,622
Front Line Care($M)
1,6521,6181,5921,526
Surgical Solutions($M)
1,6401,5541,5091,447
Laboratory and Diagnostics($M)
248293221291
United States($M)
7,1526,8576,3996,194
International($M)
533495487450
Medline Brand($M)
1,067765890830
Supply Chain Solutions($M)
204187201182
Prime Vendor Net Sales($M)3
5,2855,2264,9134,9144,4414,4184,2604,325
Prime Vendor Net Sales Growth (YoY)(%)
19.0%18.3%15.3%
Prime Vendor — Supply Chain Solutions Net Sales($M)1
3,5663,5193,3083,3072,9932,9422,8072,832
Prime Vendor — Supply Chain Solutions Growth (YoY)(%)
19.1%19.6%17.8%
Prime Vendor — Medline Brand Net Sales($M)1
1,7191,7071,6051,6071,4481,4761,4531,493
Prime Vendor — Medline Brand Growth (YoY)(%)
18.7%15.7%10.5%
Organic Net Sales Growth(%)4
10.5%11.5%10.1%14.4%
Organic Net Sales Growth ($M)($M)
748791674976
Reported Net Sales Growth(%)
10.4%11.6%10.7%14.8%
Foreign Exchange Impact on Net Sales ($M)($M)
-783417
Foreign Exchange Impact on Net Sales (%)(%)
-0.1%0.1%0.6%0.3%
Full-Year 2026 Guidance — Organic Sales Growth (Low)(%)3
10.0%9.0%8.5%8.0%
Full-Year 2026 Guidance — Organic Sales Growth (High)(%)
10.5%10.0%9.5%9.0%
Full-Year 2026 Guidance — Adjusted EBITDA (Low)($M)
3,3003,3003,5003,500
Full-Year 2026 Guidance — Adjusted EBITDA (High)($M)
3,4003,4003,6003,600
Medline Brand Segment — Net Sales($M)1
3,6373,5403,4653,7233,4113,3223,2643,3293,123
Medline Brand — Segment Adjusted EBITDA Margin(%)
25.9%30.1%22.1%21.3%24.1%26.8%25.4%24.8%
Supply Chain Solutions Segment — Net Sales($M)1
4,2194,1453,8874,0643,7043,5643,3803,4553,265
Supply Chain Solutions — Segment Adjusted EBITDA Margin(%)
4.4%4.9%4.8%5.3%5.5%5.6%5.4%4.9%
Total Segment Adjusted EBITDA (Before Corporate)($M)1
1,1271,2719521,0101,0261,0911,0129921,007
Corporate & Other Unallocated Adjusted EBITDA($M)
-167-211-176-205-167-156-144-182-127
Consolidated Long-Lived Assets, Net($M)2
5,2025,0925,1645,2105,1354,979
United States Long-Lived Assets, Net($M)
4,3644,2774,3594,4334,3934,329
International Long-Lived Assets, Net($M)
838815805777742650
Inventories — Finished Goods($M)2
4,0363,8703,9724,0213,780
Inventories — Raw Materials & Work in Process($M)
770795835748676
Inventory Valuation & Obsolescence Reserves($M)
6056564435
Unconditional Purchase Obligations — Total($M)6
710753805849
Payments Made Under Unconditional Purchase Obligations($M)
435242561374449
Purchase Obligations Due in Next Fiscal Year($M)
162162162172
Purchase Obligations Due in Year 2($M)
169169169162
Purchase Obligations Due in Year 3($M)
172172172169
Purchase Obligations Due in Year 4($M)
115115115172
Purchase Obligations Due Thereafter($M)
595959
Consolidated Adjusted EBITDA($M)6
9601,060776805859935868810
Consolidated Adjusted EBITDA Margin(%)
12.2%13.8%10.6%10.3%12.1%13.6%13.1%11.9%
Consolidated Gross Profit Margin(%)
24.5%28.8%25.0%26.4%27.7%27.5%
EBITDA Adjustment — Non-Cash LIFO & Inventory Step-Up($M)
1223294521521
EBITDA Adjustment — Stock-Based Compensation($M)
29292327151522
EBITDA Adjustment — Transaction, Integration & IPO Costs($M)
302935231211129
EBITDA Adjustment — Other Non-Core Charges($M)
1638986319755211
Adjusted Net Income($M)2
577666433
Adjusted Diluted Earnings Per Share($)
0.440.500.33
Adjusted Diluted Shares (Assuming Full Up-C Exchange)(M)
1,3191,3401,318
Non-GAAP Free Cash Flow($M)
8846043169153587584
Net Leverage Ratio (Net Debt / TTM Adjusted EBITDA)(×)6
2.502.903.103.104.90
Net Debt($M)
9,13510,07310,51910,81616,558
Trailing-Twelve-Month Adjusted EBITDA($M)
3,6013,5003,3753,4673,361
Long-Term Debt Maturities — Next 12 Months / Year 1($M)
28287676
Long-Term Debt Maturities — Year 2($M)
272772676
Long-Term Debt Maturities — Year 3($M)
8,0278,0278,535726
Long-Term Debt Maturities — Year 4($M)
28283,3428,535
Class A Common Stock Outstanding(M)1
8798778468120
Class B Common Stock (Continuing Equity Owners' Medline Holdings Units)(M)
4374374685020
Tax Receivable Agreement (TRA) Liability — Total($M)3
4,4154,4044,0213,5420
Tax Receivable Agreement Liability — Current($M)
121212
Tax Receivable Agreement Liability — Noncurrent($M)
4,4034,3924,0093,542
TRA Liability Recognized from Unit Exchanges($M)
113834793,542000
Definite-Lived Customer Relationships Intangible, Net($M)9
7,8928,0368,1838,3288,892
Indefinite-Lived Tradenames($M)
3,8303,8303,8303,8303,830
Definite-Lived Tradenames, Net($M)
1314151520
Developed Technology Intangible, Net($M)
1,6421,6581,6891,7201,817
Intangible Asset Amortization Expense($M)
176177176176177176175
Estimated Future Intangible Amortization — Next 12 Months / Year 1($M)
705704704704
Estimated Future Intangible Amortization — Year 2($M)
705704704704
Estimated Future Intangible Amortization — Year 3($M)
704702702704
Estimated Future Intangible Amortization — Year 4($M)
703701701702
Allowance for Credit Losses on Accounts Receivable($M)
148148148152108
U.S. Federal Contract Obligations to Medline — Total($M)3
27126122023525113514746.312912287.732.3
Department of Veterans Affairs (VA) Contract Obligations($M)
25124521322523310512635.711710872.823.3
Department of Defense (DoD / Defense Health Agency) Obligations($M)
00.10000.100.200000.200.100.20
Department of Health & Human Services (HHS) Obligations($M)
18.111.93.707.5114.327.918.68.6210.89.3013.16.80
FDA 510(k) Premarket Clearances — Medline1
112211123155
U.S. Medical Device Industry — Total FDA 510(k) Clearances
855923756806797886736856767793713877
FDA Medical Device Recall Events — Medline1
9527212156176551134191218819
FDA Recall Enforcement Reports — Medline
1382331176512905799197416220
FDA MAUDE Adverse Event Reports — Medline Total4
50,3793,360577398384295255310273570714246
MAUDE Device Malfunction Reports — Medline
49,9483,223449210214163119157106364578139
MAUDE Patient Injury Reports — Medline
184130124185166131129151160199131105
MAUDE Death Reports — Medline
464341706531
U.S. Medical Device Industry — Total FDA MAUDE Reports
1,189,467923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
U.S. PPI — Surgical Appliance & Supplies Manufacturing (Index)(×)5
269.30263.80253.80251.40249.60249.50248.70245.40245.10243.70240.10238.50
U.S. PPI — Surgical & Medical Instrument Manufacturing (Index)(×)
163.40162.90161.70159.60157.80156.90157.10155.20154.40154.10153.60151.00
U.S. PPI — Electromedical Apparatus Manufacturing (Index)(×)
92.8092.1092.0091.6090.7090.3090.1089.5089.3088.4088.3087.80
U.S. CPI — Medical Care Commodities (Index)(×)
404.90410.40416.80417.00416.50416.00412.60415.90414.50408.30410.10
U.S. CPI — Medical Care Services (Index)(×)
654.70650.90647.60638.40630.60623.40619.60613.00611.40605.80597.90
U.S. Census QSS — General Medical & Surgical Hospitals Revenue($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Consolidated Net Sales (GAAP)($M)9
7,8567,6857,3527,7877,1156,8866,644
Cost of Goods Sold($M)
5,9315,4705,5115,8735,2404,9814,820
Gross Profit($M)
1,9252,2151,8411,9141,8751,9051,824
Selling, General & Administrative Expenses($M)
1,2591,2951,2281,2651,1161,0731,070
Total Operating Expenses($M)
1,4251,8201,4191,4891,3011,2631,253
Operating Income($M)
500395422425574642571
Interest Expense($M)
165168165200248253244
Interest Income($M)
47492934353034
Income Before Income Taxes($M)
386235291206345359338
Income Tax Provision($M)
68965226232616
Consolidated Net Income (GAAP)($M)4
318139239193318329319
Net Income Attributable to Noncontrolling Interests($M)
12379110-2000
Net Income Attributable to Medline Inc.($M)
19859132
GAAP Diluted Earnings Per Share($)
0.220.070.16
GAAP Weighted-Average Diluted Class A Shares(M)
1,316861825
Total Assets($M)7
40,17839,35039,01438,48435,978
Cash & Cash Equivalents($M)
2,3212,3272,2361,9399555848402501,585
Accounts Receivable, Net($M)
3,7943,6613,6743,5333,219
Inventories, Net($M)
4,8064,6654,8074,7694,456
Total Current Assets($M)
12,65311,74211,18010,6798,272
Property, Plant & Equipment, Net($M)
4,7284,6974,7584,7784,595
Goodwill($M)
8,0738,0728,0768,0798,0657,532
Definite & Indefinite-Lived Intangible Assets, Net($M)
13,37713,53813,71713,89314,559
Total Liabilities($M)5
20,79220,27319,66519,19819,454
Accounts Payable($M)
1,2091,043932961869
Accrued Expenses & Other Current Liabilities($M)
1,8911,6381,5271,4521,493
Total Current Liabilities($M)
3,1292,7102,5362,4902,440
Current Portion of Long-Term Debt & Short-Term Borrowings($M)
2929777778
Long-Term Debt, Less Current Portion($M)
12,55112,54812,49512,48416,416
Total Stockholders' Equity & Partners' Capital($M)2
19,38619,07719,34919,286
Medline Inc. Stockholders' Equity($M)
11,80111,57211,27210,737
Noncontrolling Interests (Medline Holdings, LP)($M)
7,5857,5058,0778,549
Net Cash Provided by Operating Activities($M)6
1,025715412229636197682
Capital Expenditures($M)
1411119613810111098
Cash Paid for Acquisitions, Net of Cash Acquired($M)
000000-6
Depreciation & Amortization($M)
259256254261253250247
Stock-Based Compensation (Cash Flow)($M)
29292327151519
Net Cash Used in Investing Activities($M)
-980-461-96-138-101-143-92
Net Cash Used in Financing Activities($M)
-48-159-13897-161-328-9

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Medline Inc. operates on a 52- or 53-week fiscal year ending near December 31 (Q1 2026 ended March 28, 2026; Q2 2026 ended June 27, 2026; Q3 2026 ended September 26, 2026).
  • Medline completed its initial public offering on December 17, 2025 under an Up-C partnership structure holding Common Units in Medline Holdings, LP; pre-IPO historical figures reflect Medline Holdings, LP on a consistent consolidated GAAP basis.
  • Standalone Q4 flow figures not separately printed in quarterly filings are derived strictly as full-year minus nine-month year-to-date figures from the corresponding SEC filings.
  • U.S. GAAP consolidated financial statements do not include parent-only operating income statements (Medline Inc. is a holding company whose sole material asset is its equity interest in Medline Holdings, LP); consolidated-minus-standalone parent decomposition is not applicable.

Không hiện vì thiếu các kỳ gần đây (17)

  • Manufacturing, Distribution Network & Supply Chain Operations › Tracy, CA Distribution Center Fire — Inventory Loss — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q2, FY2026Q3)
  • Manufacturing, Distribution Network & Supply Chain Operations › Tracy, CA Distribution Center Fire — Fixed Asset Loss — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q2, FY2026Q3)
  • Manufacturing, Distribution Network & Supply Chain Operations › Tracy, CA Distribution Center Fire — Insurance Proceeds Recognized — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q3)
  • Manufacturing, Distribution Network & Supply Chain Operations › Medline ReNewal — Single-Use Medical Devices Reprocessed — Annual series ends prior to FY2025 (FY2019, FY2020, FY2021, FY2023); FY2024–FY2025 sustainability reports are not filed with the SEC or published in open archives
  • Manufacturing, Distribution Network & Supply Chain Operations › Medline ReNewal — Hospital Landfill Waste Diverted (Pounds) — Annual series ends prior to FY2025 (FY2019, FY2020, FY2021, FY2022, FY2023); FY2024–FY2025 sustainability reports are not filed with the SEC or published in open archives
  • Manufacturing, Distribution Network & Supply Chain Operations › Worldwide Employee Headcount (Point Count) — Annual series ends prior to FY2025 (FY2023); FY2024–FY2025 sustainability reports are not filed with the SEC or published in open archives
  • Non-GAAP Profitability, Net Leverage & Up-C Structure › IEEPA Net Tariff Refund Benefit Recognized — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q3)
  • Non-GAAP Profitability, Net Leverage & Up-C Structure › Share Repurchase Program Authorization — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q3)
  • Regulatory Surveillance, Federal Supply & Healthcare Benchmarks › FDA 510(k) Premarket Clearances — Medline › FDA Premarket Approvals (PMA) — Medline — Zero events across all periods (Medline manufactures Class I and Class II 510(k) devices rather than Class III PMA devices)
  • Consolidated GAAP Financial Statements › Total Assets › Short-Term Investments — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2025Q4, FY2026Q2, FY2026Q3)
  • Prime Vendor › Active Prime Vendor Relationships Count ('over 1,300 relationships' in Form 424B4 — disclosed only as a lower bound)
  • Prime Vendor › Five-Year Average Prime Vendor Customer Retention Rate ('greater than 98%' in Form 424B4 — disclosed only as a lower bound)
  • Supply Chain › MedTrans Private Fleet Truck Count in SEC Filings ('over 2,000' in FY2024 424B4; 'more than 2,100' in FY2025 10-K — lower bounds; FMCSA USDOT #987933 MCS-150 point census of 2,128 power units and 2,348 drivers is a single-period snapshot)
  • Supply Chain › U.S. & Global Warehouse Square Footage ('over 26 million sq. ft.' U.S. and 'over 29 million sq. ft.' global — disclosed only as lower bounds in Form 424B4 and Form 10-K)
  • Workforce › Worldwide & U.S. Employee Headcount in SEC Filings ('over 43,000' in FY2024 424B4; 'over 45,000 worldwide' and 'over 26,000 U.S.' in FY2025 10-K — disclosed only as lower bounds after FY2023)
  • Innovation & Sourcing › Granted Patents ('more than 2,300'), Cumulative 510(k)s ('more than 450'), and Global Sourcing Partners ('more than 600' — disclosed only as lower bounds in Form 10-K)
  • Commercial › 1H 2026 New Customer Signings ('more than $650 million' / 'over 65% of annual goal' in Q2 2026 release & call — lower bound and single semi-annual period)

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Medline

See a number that looks wrong?